U.S. Online Retail and Ecommerce Stock News

Symbotic Q1 2026 earnings in focus Symbotic (SYM) has opened fiscal 2026 with Q1 revenue of US$630.0 million and Basic EPS of US$0.02, setting the tone for how investors assess its path toward sustained profitability. The company has seen revenue rise from US$486.7 million in Q1 2025 to US$630.0 million in Q1 2026, while Basic EPS has shifted from a loss of US$0.03 to a profit of US$0.02 over the same period, giving this quarter a clearer view of how margins are shaping up. See our full...

Virtus Investment Partners (NYSE:VRTS) is expanding into private markets through a majority stake in Keystone National Group and a minority investment in Crescent Cove. The firm is also launching new actively managed ETFs as it adjusts its product lineup alongside recent equity outflows. These moves reshape Virtus Investment Partners' business mix beyond its traditional equity focused strategies. For investors watching NYSE:VRTS, the timing of these steps comes after a period of weaker...

If you are wondering whether AllianceBernstein Holding is fairly priced or offering value at its current level, this article walks through the key signals that matter for long term investors. The stock last closed at US$42.36, with reported returns of 2.6% over 7 days, 7.0% over 30 days, 9.6% year to date, 28.4% over 1 year, 36.5% over 3 years and 66.0% over 5 years, which gives useful context before assessing what you are paying for today. Recent share price moves have been covered...

StoneX Group’s Q1 2026 earnings put recent growth in focus StoneX Group (SNEX) opened its new fiscal year with Q1 2026 revenue of about US$38.5b and basic EPS of US$2.75, setting the tone after a year where earnings were reported to have grown 30.7%. The company has seen quarterly revenue move from US$27.6b in Q1 2025 to US$38.5b in Q1 2026, while basic EPS over that stretch ranged from US$1.29 to US$2.75, alongside trailing twelve month EPS of US$7.21 backed by net income of US$349.4m. With...

If you are wondering whether Ardent Health's current share price reflects its real worth, this article will walk you through what the numbers are saying about value. The stock last closed at US$8.58, with a 4.1% return over the past 7 days, a 7.9% decline over the last 30 days, and a 0.7% decline year to date, compared with a 42.3% decline over the past year. Recent news flow around Ardent Health has largely centered on its position within the US healthcare sector and how investors are...

Gorman-Rupp (NYSE:GRC) reported record net sales, net income, and incoming orders for the full year 2025. The company outlined operational optimization efforts that are expected to bring cost savings and support improved profitability over time. The update highlights both financial performance and changes to the company’s operating footprint that are important for shareholders to monitor. For investors tracking NYSE:GRC, the latest update comes with the stock at $59.55 and a reported 60.4%...

PAR Technology (NYSE:PAR) has expanded its partnership with Jack’s Family Restaurants, which will roll out a unified platform for point of sale, payments, loyalty, and hardware across about 300 locations. The company has also broadened its integrations with workforce management provider Netchex, linking restaurant operations more tightly with payroll and HR systems for multi location operators. PAR Technology is leaning into its role as a full stack restaurant tech provider at a time when...

Corpay (CPAY) just posted its FY 2025 results with Q4 revenue of US$1.2b and basic EPS of US$3.81, capped by trailing twelve month revenue of US$4.5b and EPS of US$15.25. The company has seen revenue move from US$1.0b in Q1 2025 to US$1.2b in Q4, while quarterly EPS ranged from US$3.46 to US$4.03 over the year, giving investors a clear view of how the top line and per share profitability have tracked through the fiscal period. With net profit margins easing over the past year, this latest...

In early February 2026, The Hanover Insurance Group reported past fourth-quarter and full-year 2025 results showing higher revenue and net income year on year, alongside earnings per share that exceeded analyst expectations despite revenue landing slightly below some forecasts. At the same time, Hanover completed a long-running share repurchase program totaling 9,073,341 shares for about US$1.17 billion since 2018, highlighting an emphasis on shareholder returns alongside improved operating...

If you are wondering whether Jefferies Financial Group at around US$56.51 is offering fair value or an opportunity, you are not alone. This article is built to help you frame that question clearly. The stock has recently been weak in the short term, with returns of a 7.7% decline over 7 days, a 14.7% decline over 30 days, and an 11.0% decline year to date. However, the 3 year and 5 year returns of 58.3% and 138.8% show a very different picture from a longer lens. Recent market commentary...

Winnebago Industries, Inc. recently announced it will redeem US$100,000,000 of its US$200,000,000 6.250% Senior Secured Notes due 2028 on February 20, 2026, at 100% of principal plus accrued and unpaid interest. This partial redemption highlights the company’s emphasis on balance sheet strength and financial flexibility, using available cash to reduce secured debt. Next, we’ll examine how this move to cut higher-cost secured debt influences Winnebago Industries’ broader investment...

BML Capital Management has exited its entire position in Alumis (NasdaqGS:ALMS). The move aligns with Alumis filing a new shelf registration. The company is also preparing to appear at several major investor conferences. BML Capital Management stepping away from Alumis puts fresh attention on how the market views the biotech name. Alumis, which focuses on drug development, now heads into a period where it is updating its capital markets toolkit through a shelf registration while also...

Uber Technologies (UBER) closed out FY 2025 with Q4 revenue of US$14.4b and basic EPS of US$0.14, alongside net income of US$296m, capping a year where trailing twelve month revenue reached US$52.0b and EPS came in at US$4.82. Over recent quarters, the company has seen revenue move from US$11.5b in Q1 2025 to US$13.5b in Q3 and then US$14.4b in Q4. Quarterly EPS shifted from US$0.85 in Q1 to US$3.18 in Q3 before landing at US$0.14 in the latest period, setting up a results season that puts...

If you are wondering whether Roper Technologies is starting to look interesting at its current share price, this article will walk through what that might mean for you as an investor. The stock last closed at US$351.00, with returns of a 3.8% decline over 7 days, 19.6% decline over 30 days, 19.2% decline year to date, 39.4% decline over 1 year, 16.6% decline over 3 years, and 9.6% decline over 5 years. Recent news around Roper has focused on its positioning as a diversified software and...

If you are trying to work out whether Materion’s share price still offers value at its current level, the key question is how that price lines up against what the business may be worth. The stock last closed at US$145.83, with returns of 2.8% over 7 days, 8.3% over 30 days, 13.5% year to date, 43.6% over 1 year, 73.7% over 3 years and 115.6% over 5 years. This naturally raises questions about how much of the story is already reflected in the price. Recent news coverage has focused on...

If you are wondering whether Aptiv's current share price lines up with its underlying value, you are not alone. This article is designed to help you frame that question clearly. Aptiv's stock last closed at US$79.72, with returns of 1.1% over 7 days, a 3.5% decline over 30 days, 1.6% year to date, a 25.6% gain over 1 year, and declines of 31.3% and 48.2% over 3 and 5 years respectively. Taken together, these figures give a mixed signal about growth potential and risk perception. Recent...

Structure Therapeutics (NasdaqGM:GPCR) has advanced its lead obesity candidate GSBR-1290 into phase 2 clinical trials as an oral treatment. The move comes as the company draws increased attention for targeting the obesity market with a pill-based approach rather than injectables. Analyst optimism and early discussion about potential takeovers have put fresh focus on the stock. Structure Therapeutics, trading under NasdaqGM:GPCR, is drawing fresh interest after pushing GSBR-1290 into phase...

Tennant Company set the date for its 2026 annual meeting of shareholders. The company also announced the deadline for shareholders to nominate director candidates for the 2026 board election. The update outlines the timetable that will guide board nominations and voting for NYSE:TNC. Tennant, trading on the NYSE under ticker NYSE:TNC, recently closed at $80.84. The stock is up 5.5% over the past week, 5.0% over the past month, and 9.3% year to date, while showing a 4.1% decline over the...

To the annoyance of some shareholders, Doximity, Inc. ( NYSE:DOCS ) shares are down a considerable 27% in the last...

The New York Times (NYT) closed out FY 2025 with Q4 revenue of US$802.3 million and basic EPS of US$0.80, compared with US$719.5 million of revenue and EPS of US$0.75 in the prior year’s Q4, pointing attention squarely to how efficiently the business is turning its top line into profit. Over the past six quarters, the company has seen quarterly revenue move from US$633.6 million in Q3 2024 to US$694.1 million in Q3 2025 and then to US$802.3 million in Q4 2025, while basic EPS ranged from...

UiPath, Inc. ( NYSE:PATH ) shares have had a horrible month, losing 30% after a relatively good period beforehand. The...

As you might know, Broadridge Financial Solutions, Inc. ( NYSE:BR ) just kicked off its latest quarterly results with...

FDA accepts Exelixis' New Drug Application for zanzalintinib plus atezolizumab in metastatic colorectal cancer. The application is based on pivotal trial data for patients with advanced disease. This step moves the investigational combination closer to potential commercial use in the United States. For investors watching NasdaqGS:EXEL, this FDA filing milestone is an important datapoint in the company’s oncology pipeline. Exelixis focuses on cancer therapies, and colorectal cancer is a...

Allstate (ALL) just wrapped up FY 2025 with Q4 revenue of US$17.3b and basic EPS of US$14.55, capping off a trailing twelve month stretch where revenue reached US$67.7b and EPS came in at US$38.56 alongside year over year earnings growth of 123.4%. Over the past few quarters, the company has seen revenue move from US$16.5b and EPS of US$7.16 in Q4 2024 to US$16.6b and EPS of US$7.86 in Q2 2025, then to US$17.3b and EPS of US$14.55 in Q4 2025, setting up a story where stronger profitability...